Business Wire

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
News Medical

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age ...
Healio

VIDEO: Subcutaneous injection shows promise for wet AMD, DME

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for ...
Seeking Alpha

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...
Seeking Alpha

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and ...
Nasdaq

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME

4D Molecular Therapeutics has initiated its first Phase 3 trial for 4D-150 in wet AMD and expanded its clinical pipeline. 4D Molecular Therapeutics (4DMT) has announced significant progress in its ...

EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets’ Ophthalmology Conference that ...
MedPage Today

Anti-VEGF Injections Versus Surgery for Submacular Hemorrhage in Age-Related Macular Degeneration

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...
Healio

Patients with geographic atrophy require careful screening, opportunity for treatment

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” ...
MedPage Today

What's on the Horizon for Age-Related Macular Degeneration?

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...
Nasdaq

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...